You're asking about a specific chemical compound: **1-[2-(dimethylamino)ethyl]-3-(2,4-dimethylphenyl)-1-(thiophen-2-ylmethyl)thiourea**. While I can't give you specific research insights, I can break down its structure and why it might be interesting to researchers.
**Understanding the Chemical Structure**
* **Thiourea:** The core of the molecule is a thiourea group. This is similar to a urea molecule but with a sulfur atom instead of oxygen. Thioureas have diverse biological activities and are often used in drug discovery.
* **Substituents:** The compound has several other groups attached to the thiourea core:
* **(2,4-dimethylphenyl):** A benzene ring with two methyl groups. This aromatic ring is a common building block in many organic molecules and can influence the compound's properties.
* **(thiophen-2-ylmethyl):** A five-membered ring containing sulfur (thiophene) with a methylene group attached. Thiophenes are known for their biological activity and are often incorporated into drug-like molecules.
* **(2-(dimethylamino)ethyl):** An aliphatic chain with a dimethylamino group. This group can make the molecule more water-soluble and potentially interact with biological targets.
**Possible Research Significance**
Given the structure, this compound could be of interest for research in various fields:
* **Pharmacology/Drug Discovery:**
* Thioureas are known for their ability to interact with proteins and enzymes. The specific substituents on this thiourea could make it a potential drug candidate for treating various diseases.
* The dimethylamino group might enhance its ability to bind to specific receptors.
* The aromatic rings and thiophene ring could contribute to its activity and/or pharmacokinetic properties.
* **Materials Science:**
* Thioureas are sometimes used in the synthesis of polymers and other materials with unique properties. This compound could be investigated for its potential in creating new materials.
* **Analytical Chemistry:**
* The compound might be useful as a reagent or standard in analytical chemistry. Its unique structure could allow for specific detection or analysis of certain substances.
**Important Considerations:**
* **Specificity:** The specific properties and activity of this compound are unknown without experimental data.
* **Research Context:** The significance of this compound depends heavily on the specific research goals of the scientists involved.
**To find out more about this compound, you would need to:**
1. **Look for scientific publications:** Search databases like PubMed or Google Scholar using the compound's name or a similar structure.
2. **Contact researchers:** Reach out to scientists working in related fields to see if they have any information on this compound.
Remember, scientific research is a dynamic process, and the importance of a compound can change as new discoveries are made.
ID Source | ID |
---|---|
PubMed CID | 3390606 |
CHEMBL ID | 1470628 |
CHEBI ID | 105116 |
Synonym |
---|
smr000311238 |
MLS000689439 , |
n-[2-(dimethylamino)ethyl]-n'-(2,4-dimethylphenyl)-n-(thien-2-ylmethyl)thiourea |
CHEBI:105116 |
AKOS002117268 |
HMS2713K13 |
CHEMBL1470628 |
1-[2-(dimethylamino)ethyl]-3-(2,4-dimethylphenyl)-1-(thiophen-2-ylmethyl)thiourea |
bdbm88767 |
cid_3390606 |
1-[2-(dimethylamino)ethyl]-3-(2,4-dimethylphenyl)-1-(2-thenyl)thiourea |
3-[2-(dimethylamino)ethyl]-1-(2,4-dimethylphenyl)-3-[(thiophen-2-yl)methyl]thiourea |
Q27182809 |
SR-01000582633-1 |
sr-01000582633 |
Class | Description |
---|---|
thioureas | Compounds of general formula RR'NC(=S)NR''R'''. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 14.0919 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 15.8489 | 0.0184 | 6.8060 | 14.1254 | AID624417 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 31.6228 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 32.6294 | 0.0041 | 10.8903 | 31.5287 | AID504466 |
hypothetical protein, conserved | Trypanosoma brucei | Potency | 12.5893 | 0.2239 | 11.2451 | 35.4813 | AID624173 |
regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 19.9526 | 0.5318 | 15.4358 | 37.6858 | AID504845 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 39.8107 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 89.1251 | 0.3548 | 28.0659 | 89.1251 | AID504847 |
nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 25.9290 | 0.0041 | 9.9848 | 25.9290 | AID504444 |
serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 8.4368 | 0.1683 | 16.4040 | 67.0158 | AID720504 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 10.0000 | 0.0079 | 8.2332 | 1,122.0200 | AID2551 |
geminin | Homo sapiens (human) | Potency | 23.1093 | 0.0046 | 11.3741 | 33.4983 | AID624297 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
tyrosine-protein phosphatase non-receptor type 11 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 3.3700 | 0.1600 | 3.3759 | 9.8800 | AID602367 |
dual specificity protein phosphatase 3 | Homo sapiens (human) | IC50 (µMol) | 1.3600 | 0.4000 | 9.3610 | 90.0000 | AID602374 |
tyrosine-protein phosphatase non-receptor type 5 isoform a | Homo sapiens (human) | IC50 (µMol) | 40.3000 | 4.1700 | 12.5457 | 19.0000 | AID602372; AID624207 |
tyrosine-protein phosphatase non-receptor type 22 isoform 1 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.4800 | 2.6449 | 8.3270 | AID624241 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |